One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Dr. Reddy's Laboratories Limited logo
Dr. Reddy's Laboratories Limited RDY
$ 14.88 0.13%
report update icon

Quarterly report 2025-Q4
added 11-16-2026

Dr. Reddy's Laboratories Limited Income Statement 2025-2011 | RDY

Brief overview of income trends at Dr. Reddy's Laboratories Limited

The conclusions below are based on five years of reported results. Revenue at Dr. Reddy's Laboratories Limited moved from 175 billion INR in 2020 to 326 billion INR in 2025. The total change was +86.4%, with a CAGR of approximately 13.3%. Top-line growth remained consistently strong over the period.

Gross profit changed from 94 billion INR to 190 billion INR (+102.6%). The cost base moved more slowly than the top line, which supported margins. The gross margin was 53.8% at the start and 58.5% at the end. The business retained more gross profit from each unit of revenue.

The operating result measured by EBITDA moved from 45.2 billion INR to 71.8 billion INR, or +58.8%. EBITDA underperformed the top-line trend. The EBITDA share of revenue changed from 25.9% to 22.1%. Operating return per unit of revenue declined.

The net result moved from 19.5 billion INR to 57.2 billion INR, or +193.6%. Net profit ended the five years at a local peak.

Conclusion

The financial profile remains mixed, with strengths and risks moving in different directions. The financial profile benefits from a stronger final result, a larger revenue base and better sales economics. Caution is warranted because of a declining EBITDA margin. Investors should continue to monitor margins, costs, and earnings quality.

Annual Income Statement Dr. Reddy's Laboratories Limited

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

12.3 B 11.6 B 9.27 B 1.83 B 10.8 B 8.49 B -2.18 B -1.68 B -2.12 B -4.01 B -4.57 B 8.88 B 11.4 B 10.2 B 8.28 B

Shares

833 M 832 M 830 M 166 M 166 M 166 M -52 M -52 M -52 M -88 M -88 M 197 M 302 M 302 M 211 M

Historical Prices

14.7 13.9 11.2 11.1 65.4 71 40.1 37 36.5 43.7 44.5 48.2 38.9 31.4 27.5

Net Income

57.2 B 55.7 B 45.1 B 23.6 B 17.2 B 19.5 B - - - - - - - - 310 M

Revenue

326 B 279 B 246 B 214 B 190 B 175 B 2.22 B 2.18 B 2.17 B 2.34 B 2.38 B 2.2 B - - 1.68 B

Cost of Revenue

135 B 116 B 107 B 101 B 86.6 B 80.6 B 70.4 B 65.7 B 62.5 B 62.4 B - - - - -

Gross Profit

190 B 164 B 139 B 114 B 103 B 94 B 1.21 B 1.17 B 1.21 B 1.39 B 1.37 B 1.26 B - - 904 M

Operating Income

71.8 B 67.7 B 57.1 B 29.5 B 24.3 B 16 B 20.9 B 11.9 B 13.5 B 29.6 B - - - - -

Interest Expense

2.83 B 1.71 B 1.43 B 958 M 970 M 983 M 889 M 788 M 634 M 826 M - - - - -

EBITDA

71.8 B 67.7 B 57.1 B 29.5 B 24.3 B 45.2 B 176 M 180 M 174 M 155 M 130 M 118 M 102 M 102 M 372 M

Operating Expenses

119 B 95.9 B 82.2 B 84.4 B 78.8 B 61.2 B 63.8 B 64.3 B 64.8 B 62.6 B 59 B 49.8 B 38.9 B 34 B 27.6 B

General and Administrative Expenses

93.9 B 77.2 B 68 B 62.1 B 54.6 B 50.1 B 707 M 720 M 715 M 690 M 683 M 646 M - - 532 M

All numbers in INR currency

Quarterly Income Statement Dr. Reddy's Laboratories Limited

2025-Q4 2025-Q1 2024-Q4 2024-Q1 2023-Q4 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- 833 M - 832 M - 830 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- 57.2 B - 55.7 B - 45.1 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- 326 B - 279 B - 246 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- 135 B - 116 B - 107 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- 190 B - 164 B - 139 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- 71.8 B - 67.7 B - 57.1 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- 2.83 B - 1.71 B - 1.43 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- 71.8 B - 67.7 B - 57.1 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- 119 B - 95.9 B - 82.2 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- 93.9 B - 77.2 B - 68 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in INR currency

The income statement is one of the three key financial reports of a company Dr. Reddy's Laboratories Limited (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ММЦБ ММЦБ
GEMA
- - - russiaRussia
Lyra Therapeutics Lyra Therapeutics
LYRA
- - $ 24.9 M usaUSA
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
Промомед Промомед
PRMD
- - - russiaRussia
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
ESSA Pharma ESSA Pharma
EPIX
- - $ 8.86 M canadaCanada
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Merus N.V. Merus N.V.
MRUS
- - $ 5.78 B niderlandNiderland
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Annexon Annexon
ANNX
$ 3.11 -8.94 % $ 482 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
- 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
- - $ 35.3 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
- -18.25 % $ 5.04 M israelIsrael
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
- 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
- -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
- - $ 69.7 B britainBritain
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
- -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
- - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
- 31.87 % $ 1.61 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
- - $ 728 M usaUSA